UroGen Pharma Ltd. Annual Operating Income (Loss) in USD from 2015 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
UroGen Pharma Ltd. quarterly/annual Operating Income (Loss) history and growth rate from 2015 to 2023.
  • UroGen Pharma Ltd. Operating Income (Loss) for the quarter ending September 30, 2024 was -$17.5M, a 30% decline year-over-year.
  • UroGen Pharma Ltd. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$83.7M, a 17.6% decline year-over-year.
  • UroGen Pharma Ltd. annual Operating Income (Loss) for 2023 was -$65.5M, a 17.1% increase from 2022.
  • UroGen Pharma Ltd. annual Operating Income (Loss) for 2022 was -$79M, a 14.4% increase from 2021.
  • UroGen Pharma Ltd. annual Operating Income (Loss) for 2021 was -$92.3M, a 27.2% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$65.5M +$13.5M +17.1% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-14
2022 -$79M +$13.3M +14.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 -$92.3M +$34.4M +27.2% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-24
2020 -$127M -$17.3M -15.8% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-21
2019 -$109M -$32.3M -41.8% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-18
2018 -$77.2M -$57.2M -287% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-02
2017 -$20M -$20.7M -2600% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-02
2016 $798K +$13.2M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 -$12.4M Jan 1, 2015 Dec 31, 2015 20-F 2018-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.